The prevalence of coronary heart disease (CHD) in China has been on a steady rise, with the 2024 Report on Cardiovascular Health and Disease in China indicating that 8.368 million hospitalizations for CHD occurred in 2023. Alarmingly, 77% of CHD-related deaths are attributed to high cholesterol levels. This grim statistic underscores the critical importance of effective treatment options, leading many patients and their families to ask, "Which medication is most effective for treating CHD?"
Foundation of Treatment: The Pivotal Role of Statins
The cornerstone of CHD management lies in combating atherosclerosis, with a primary focus on reducing low-density lipoprotein cholesterol (LDL-C), often referred to as "bad cholesterol." Statins, a class of drugs widely used in lipid-lowering therapy, play a crucial role in this process. Beyond their lipid-lowering effects, statins have been shown to inhibit vascular smooth muscle cell proliferation, improve endothelial function, stabilize plaques, and reduce platelet aggregation and inflammation.
However, some patients encounter limitations with monotherapy, such as suboptimal LDL-C reduction or increased risk of adverse effects when higher doses are required to achieve target levels.
Combination Therapy: Synergistic Benefits
When single-agent statin therapy is insufficient, the addition of a cholesterol absorption inhibitor is recommended by both domestic and international guidelines. The 2023 Chinese Guidelines for Lipid Management specifically advise initiating treatment with a moderate-intensity statin for confirmed CHD patients. For those who do not reach their LDL-C targets, the guidelines recommend combining a cholesterol absorption inhibitor.
One notable option is Cesame Hyzetimibe, the first domestically developed second-generation cholesterol absorption inhibitor in China. This medication selectively inhibits intestinal cholesterol absorption, complementing the "synthesis inhibition" mechanism of statins and enhancing overall efficacy. Clinical data from Chinese studies show that 10 mg/day of Cesame Hyzetimibe alone can lower LDL-C by approximately 15% compared to placebo. When combined with a statin at 20 mg/day, it further reduces LDL-C by about 16% compared to statin monotherapy. This combination can achieve an LDL-C reduction of over 50%, comparable to high-intensity statin therapy, while also stabilizing and reversing plaques and reducing the risk of cardiovascular events. The safety and tolerability profile of this combination is favorable.
Clinical research indicates that Cesame Hyzetimibe is efficiently converted in the small intestine, with approximately 98-99% transforming into its active metabolite, glucuronide conjugate. This rapid conversion allows for quick onset of action, providing early benefits to patients. Additionally, Cesame Hyzetimibe is excreted via both hepatic and renal pathways, with a total clearance rate of about 93%. This dual-excretion route minimizes the burden on the liver and kidneys. The product's prescribing information states that no dose adjustment is necessary for patients with mild to moderate hepatic impairment, addressing a significant gap in oral lipid-lowering therapies for this patient population.
Lifestyle Management: Preventive Measures
While pharmacological interventions are essential, they should be complemented by a healthy lifestyle. Patients should adhere to a diet low in salt, fat, and cholesterol, incorporating plenty of vegetables, fruits, and whole grains. They should also maintain a healthy weight, quit smoking, limit alcohol consumption, and engage in regular, moderate exercise under medical supervision. Regular monitoring of lipid levels and liver function, along with ongoing communication with healthcare providers, is vital for ensuring the long-term effectiveness and safety of the treatment regimen.